Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

Lindsay Claxton,*, Robert Hodgson, William Malcom, Ruth Jacob, Matthew Taylor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Previously developed models in ophthalmology have generally used a Markovian structure. There are a number of limitations with this approach, most notably the ability to base patient outcomes on best-corrected visual acuity (BCVA) in both eyes, which may be overcome using a different modelling structure. Simulation modelling allows for this to be modelled more precisely, and therefore may provide more accurate and relevant estimates of the cost effectiveness of ophthalmology interventions.
Original languageEnglish
Pages (from-to)1-12
Number of pages13
Early online date27 Oct 2016
Publication statusPublished - Oct 2016

Bibliographical note

This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details

Cite this